EPISODE · Feb 17, 2021 · 26 MIN
Navigating Regulatory Pathways: Orthocell Moves Into New Markets
from The MTPConnect Podcast · host MTPConnect
In this week’s podcast, we travel to Perth to talk to regenerative medicine company Orthocell about gaining TGA, EU and US FDA approval to market its CelGro collagen membrane for dental and jaw bone surgeries. CelGro is a collagen scaffold that supports tissue reconstruction and repair. Orthocell CEO Paul Anderson discusses the regulatory approach for markets in Australia, Europe and the United States, and the setup of their dedicated and licenced GMP manufacturing facility in Perth. He shares some words of advice for medtech and medical device entrepreneurs too. This is a must-listen to episode for SMEs and start-ups keen to learn more about commercialising regenerative medicines!
Embed this episode
What this episode covers
In this week’s podcast, we travel to Perth to talk to regenerative medicine company Orthocell about gaining TGA, EU and US FDA approval to market its CelGro collagen membrane for dental and jaw bone surgeries. CelGro is a collagen scaffold that supports tissue reconstruction and repair. Orthocell CEO Paul Anderson discusses the regulatory approach for markets in Australia, Europe and the United States, and the setup of their dedicated and licenced GMP manufacturing facility in Perth. He share...
NOW PLAYING
Navigating Regulatory Pathways: Orthocell Moves Into New Markets
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.